CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
T 细胞 TET2 缺失解除抗肿瘤 CAR-T 细胞治疗的刹车
英文原题：T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy.
查看英文原题
T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞要维持抗肿瘤应答，必须在体内保持功能性持续存留。近期Jain等人发现，在CAR-T 细胞中破坏TET2可导致抗原非依赖性CAR-T 细胞过度增殖，从而增强小鼠肿瘤控制；这一发现凸显了表观遗传策略改善T细胞癌症免疫疗法的潜力。
展开英文摘要原文
Functional persistence of chimeric antigen receptor (CAR) T cells is required for sustaining an antitumor response. Recently, Jain et al. revealed that disruption of TET2 in CAR T cells resulted in antigen-independent CAR T cell hyperproliferation that enhanced tumor control in mice, highlighting the potential of epigenetic strategies to improve T cell-based cancer immunotherapy.
论文信息
- 作者
- Zebley CC、Youngblood B
- 第一作者单位
- Department of Immunology, St Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: Caitlin.Zebley@stjude.org.United States
- 通讯作者单位
- Department of Immunology, St Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: Benjamin.Youngblood@stjude.org.United States
- 文献类型
- 非美国政府资助研究 · 美国 NIH 资助研究
- 期刊
- Trends in immunology2023 Jun
- 原文标识
- PubMed 36959018 · DOI 10.1016/j.it.2023.03.008